drugset / Trial / NCT00612456
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
Timeline
- Start
- 2008-03-05
- Primary completion
- 2009-01-01
- Completion
- 2009-06-17
Outcome
Missed primary endpoint
registry Pazopanib 5 mg/mL TID; p = 0.6241; Mean Difference (Final Values) 5.83 (95% CI -31.05 to 42.71) NCT00612456 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 2 mg/ml | Topical |
| Subject | Pazopanib | Small molecule | 5 mg/ml | Topical |